Biocon Limited
NSE: BIOCON BSE: BIOCON
Prev Close
331.3
Open Price
335.8
Volume
1,860,996
Today Low / High
329.2 / 335.8
52 WK Low / High
262.15 / 404.7
Range
315 - 348
Prev Close
331.2
Open Price
335.05
Volume
34,643
Today Low / High
329.05 / 335.05
52 WK Low / High
262.3 / 404.6
Range
315 - 349
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 331.9 (target range: 315 - 348), reflecting a change of 0.6 (0.1811%). On the BSE, it is listed at 331.95 (target range: 315 - 349), showing a change of 0.75 (0.22645%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Biocon Limited Graph
Biocon Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Biocon Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 331.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 331.95 | 335.27 | 301.74 - 368.80 |
338.59 | 270.87 - 406.31 | ||
341.91 | 239.34 - 444.48 | ||
Bearish Scenario | 331.95 | 328.63 | 295.77 - 361.49 |
325.31 | 260.25 - 390.37 | ||
321.99 | 225.39 - 418.59 |
Overview of Biocon Limited
ISIN
INE376G01013
Industry
Biotechnology
Vol.Avg
2,932,380
Market Cap
398,479,140,000
Last Dividend
0.5
Official Website
IPO Date
2004-04-07
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of BIOCON
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2024-07-05 | July 05, 24 | 0.5 | 0.5 | 2024-07-05 | 2024-08-23 | |
2023-07-07 | July 07, 23 | 1.5 | 1.5 | 2023-07-07 | 2023-09-08 | |
2022-06-30 | June 30, 22 | 0.5 | 0.5 | 2022-07-01 | 2022-08-28 | |
2019-07-18 | July 18, 19 | 0.5 | 0.5 | 2019-07-19 | 2019-08-02 | 2019-04-25 |
2018-07-19 | July 19, 18 | 0.5 | 1 | 2018-07-20 | 2018-08-26 | 2018-04-26 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 14,755.70 Cr | 5,582.20 Cr | 9,173.50 Cr | 0.6217 | 1,237.80 Cr | 2,665.50 Cr | 5,083.20 Cr | 1,022.50 Cr | 8.55 | 4,152.60 Cr | 0.0693 |
2023-03-31 | 11,174.20 Cr | 3,663.10 Cr | 7,511.10 Cr | 0.6722 | 613.20 Cr | 265.10 Cr | 1,564.30 Cr | 462.70 Cr | 3.88 | 2,596.20 Cr | 0.0414 |
2022-03-31 | 8,024.80 Cr | 2,723.60 Cr | 5,301.20 Cr | 0.6606 | 502.80 Cr | 186.90 Cr | 1,158.30 Cr | 648.40 Cr | 5.44 | 2,071.80 Cr | 0.0808 |
2021-03-31 | 6,970.10 Cr | 2,210.20 Cr | 4,759.90 Cr | 0.6829 | 395.00 Cr | 252.90 Cr | 953.90 Cr | 740.50 Cr | 6.24 | 1,919.90 Cr | 0.1062 |
2020-03-31 | 6,211.50 Cr | 2,054.30 Cr | 4,157.20 Cr | 0.6693 | 307.70 Cr | 151.30 Cr | 1,052.00 Cr | 748.20 Cr | 6.32 | 1,832.00 Cr | 0.1205 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 1,233.40 Cr | 56,070.70 Cr | 30,795.90 Cr | 19,783.7000 Cr | 16,276.70 Cr | 15,043.30 Cr | 4,943.90 Cr | 11,977.80 Cr | 634.10 Cr | 310.70 Cr | -466.40 Cr | 15,358.8000 Cr |
2023-03-31 | 1,323.50 Cr | 52,042.80 Cr | 29,554.00 Cr | 17,866.9000 Cr | 18,018.80 Cr | 16,695.30 Cr | 4,243.70 Cr | 10,122.60 Cr | 899.00 Cr | 290.10 Cr | 867.30 Cr | 8,510.7000 Cr |
2022-03-31 | 662.60 Cr | 20,394.00 Cr | 10,924.00 Cr | 8,432.5000 Cr | 5,146.60 Cr | 4,484.00 Cr | 2,298.20 Cr | 9,415.50 Cr | 1,260.90 Cr | 1,215.10 Cr | 370.20 Cr | 3,828.0000 Cr |
2021-03-31 | 952.60 Cr | 18,522.30 Cr | 10,014.70 Cr | 7,626.9000 Cr | 4,481.10 Cr | 3,528.50 Cr | 1,866.60 Cr | 7,964.10 Cr | 1,261.50 Cr | 1,025.30 Cr | 882.10 Cr | 4,210.1000 Cr |
2020-03-31 | 909.30 Cr | 14,443.80 Cr | 7,060.70 Cr | 6,705.8000 Cr | 2,715.30 Cr | 1,806.00 Cr | 1,435.90 Cr | 7,098.00 Cr | 1,225.80 Cr | 949.40 Cr | 108.50 Cr | 4,008.0000 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 2,953.9000 Cr | -1,004.5000 Cr | -2,332.7000 Cr | 1,022.3000 Cr | -380.4000 Cr | 919.5000 Cr | -1,931.6000 Cr | 1,022.5000 Cr | -1,271.2000 Cr | -203.0000 Cr | -886.4000 Cr |
2023-03-31 | 1,852.5000 Cr | -14,281.8000 Cr | 13,048.7000 Cr | 126.2000 Cr | 641.1000 Cr | 1,294.8000 Cr | -1,726.3000 Cr | 643.0000 Cr | 12,415.9000 Cr | -71.8000 Cr | 886.2000 Cr |
2022-03-31 | 1,176.6000 Cr | -1,699.1000 Cr | 242.1000 Cr | -748.2000 Cr | -243.3000 Cr | 653.7000 Cr | -1,924.8000 Cr | 771.6000 Cr | 321.3000 Cr | 0.0000 Cr | -414.0000 Cr |
2021-03-31 | 1,159.7000 Cr | -3,624.7000 Cr | 2,564.0000 Cr | -586.6000 Cr | 72.3000 Cr | 897.0000 Cr | -1,746.3000 Cr | 846.2000 Cr | 1,888.8000 Cr | 0.0000 Cr | -445.4000 Cr |
2020-03-31 | 1,283.1000 Cr | -1,558.9000 Cr | 387.6000 Cr | -553.4000 Cr | 165.4000 Cr | 824.7000 Cr | -1,836.5000 Cr | 870.9000 Cr | 18.6000 Cr | -70.1000 Cr | -380.6000 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 3,773.00 Cr | 1,359.30 Cr | 2,413.70 Cr | 0.6397 | 292.30 Cr | 25.10 Cr | 0.21 | 804.70 Cr | 0.0067 |
2024-09-30 | 3,545.00 Cr | 1,182.60 Cr | 2,362.40 Cr | 0.6664 | 221.10 Cr | -16.00 Cr | -0.13 | 743.90 Cr | -0.0045 |
2024-06-30 | 3,432.90 Cr | 2,311.40 Cr | 1,121.50 Cr | 0.3267 | 215.00 Cr | 659.70 Cr | 5.49 | 620.40 Cr | 0.1922 |
2024-03-31 | 3,917.10 Cr | 2,404.40 Cr | 1,512.70 Cr | 0.3862 | 508.90 Cr | 135.50 Cr | 1.13 | 955.70 Cr | 0.0346 |
2023-12-31 | 3,548.70 Cr | 1,231.80 Cr | 2,316.90 Cr | 0.6529 | 1,053.70 Cr | 660.00 Cr | 5.50 | 1,513.50 Cr | 0.1860 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2024-09-30 | 1,687.70 Cr | 1,429.50 Cr | 3,117.20 Cr | 6,129.20 Cr | 4,965.10 Cr | 15,153.50 Cr | 12,453.40 Cr | 57,127.90 Cr | 30,407.90 Cr |
2024-06-30 | 1,919.00 Cr | 814.00 Cr | 2,574.00 Cr | 0.00 Cr | 5,037.00 Cr | 2,574.00 Cr | 12,133.00 Cr | 55,671.00 Cr | -25,274.80 Cr |
2024-03-31 | 2,258.70 Cr | 315.60 Cr | 2,574.30 Cr | 6,230.60 Cr | 4,943.90 Cr | 15,179.20 Cr | 11,977.80 Cr | 56,070.70 Cr | 30,795.90 Cr |
2023-12-31 | 1,819.00 Cr | 1,927.00 Cr | 3,746.00 Cr | 4,678.00 Cr | 5,023.00 Cr | 14,828.00 Cr | 11,902.00 Cr | 55,531.00 Cr | 30,398.00 Cr |
2023-09-30 | 644.40 Cr | 3,286.10 Cr | 3,930.50 Cr | 4,033.20 Cr | 4,910.80 Cr | 14,069.90 Cr | 10,922.10 Cr | 54,576.90 Cr | 30,299.50 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-06-30 | 659.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 135.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | 660.00 Cr | 829.00 Cr | 0.00 Cr | 0.00 Cr | -169.90 Cr | 1,819.00 Cr | 1,988.90 Cr | 0.00 Cr | 829.00 Cr |
2023-09-30 | 125.60 Cr | 778.60 Cr | 0.00 Cr | 0.00 Cr | -25.10 Cr | 1,988.90 Cr | 2,014.00 Cr | 0.00 Cr | 778.60 Cr |
2023-06-30 | 101.40 Cr | 716.00 Cr | 0.00 Cr | 0.00 Cr | 690.20 Cr | 2,014.00 Cr | 1,323.80 Cr | 0.00 Cr | 716.00 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
2019-06-12 | June 12, 19 | 2:1 |
2017-06-15 | June 15, 17 | 3:1 |
2008-09-11 | September 11, 08 | 2:1 |
Similar Stocks: Biotechnology
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Biocon Limited | BIOCON | ₹331.90 | ₹398,479,140,000.00 | ₹1,860,996.00 |
Piramal Pharma Limited | PPLPHARMA | ₹220.76 | ₹292,672,172,632.00 | ₹3,206,567.00 |
Syngene International Limited | SYNGENE | ₹724.60 | ₹290,777,127,354.00 | ₹309,960.00 |
Concord Biotech Limited | CONCORDBIO | ₹1,712.30 | ₹179,134,319,260.00 | ₹167,947.00 |
Blue Jet Healthcare Limited | BLUEJET | ₹742.40 | ₹128,780,727,808.00 | ₹402,801.00 |
Jubilant Ingrevia Limited | JUBLINGREA | ₹674.95 | ₹107,506,805,443.00 | ₹165,388.00 |
Supriya Lifescience Limited | SUPRIYA | ₹743.80 | ₹59,863,106,640.00 | ₹485,094.00 |
Dishman Carbogen Amcis Limited | DCAL | ₹210.73 | ₹33,038,902,663.00 | ₹169,506.00 |
Panacea Biotec Limited | PANACEABIO | ₹504.80 | ₹30,919,375,571.00 | ₹556,110.00 |
Zota Health Care Limited | ZOTA | ₹884.35 | ₹24,657,917,174.00 | ₹61,116.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born:
Gender: female
Year Born: 1973
Gender: male
Year Born:
Gender: Not Specified
Year Born: 1953
Gender: male
Year Born:
Gender: male
Year Born: 1978
Gender: female
Year Born: 1966
Gender: male
Year Born: 1973
Gender: male
Year Born:
FAQs about Biocon Limited
The CEO is Mr. Siddharth Mittal BCom, CA, CPA.
The current price is ₹331.90.
The range is ₹262.15-404.7.
The market capitalization is ₹39,847.91 crores.
The dividend yield is 0.15%.
The P/E ratio is 49.32.
The company operates in the Healthcare sector.
Overview of Biocon Limited (ISIN: INE376G01013) is a leading Biotechnology in India. With a market capitalization of ₹39,847.91 crores and an average daily volume of 2,932,380 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.5.